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Background: Patients with thoracic malignancies may have increased risk for COVID-
19 mortality. This risk may be attributable to age, comorbidities, smoking history,
pulmonary disease burden and cancer-directed therapies.
Methods: TERAVOLT is a global consortium examining outcomes and assessing risk
factors associated with mortality of patients with thoracic malignancies and COVID-19
infection.
Results: As of July 15, 2020, 1012 patients from 20 countries have been entered;
median age was 68 with 58 % male, 80% current/former smokers, most common
comorbidities of HTN (49%) & COPD (26%); 82% NSCLC, 68 % patients with stage IV
disease at COVID diagnosis, 65% on treatment (38% chemotherapy, 26% immune
checkpoint inhibitor (ICI), 16 % targeted tyrosine kinase inhibitor (TKI). Of these, 72%
were hospitalized; 56% of patients developed complications, most frequently pneu-
monia (40%) and 47% who did not have prior oxygen therapy required it. 32% of
patients died during their COVID-19 infection. Only 33 % of patients continued their
oncology treatment after infection. Patients presenting with pneumonia (OR 2.7 2-
3.5), consolidation (OR 2 CI 1,5-2,8), bilateral lung abnormalities (OR 2,8 CI 2-3,9) and
pleural effusion (OR 2,7 CI 1,8-4) were at increased risk of mortality. In multivariate
analysis age  65 (OR 1,53 CI 1,11-2,1), active smoking (OR 2 CI 1,3-3), higher stage of
cancer (OR 1,9 CI 1,3-2,7), ECOG PS 2 (OR 3,7 CI 2,7-5), steroids prior to COVID
diagnosis (OR 1,8 CI 1,2-2,7), were associated with increased risk of death, while
chemotherapy and TKI therapy use were not and interestingly patients on immuno-
therapy appeared to be at decreased risk for mortality (OR 0,6 CI 0,5-0,97).
Conclusions: Facing this ongoing global pandemic, TERAVOLT is the largest thoracic
malignancy database confirming the high risk for COVID-19 mortality in this specific
patient group. Physicians need to evaluate the risk of mortality from COVID-19 based
on age, smoking status, stage of cancer, performance status, need for steroids and
specific therapy in order to determine the appropriateness for cancer therapy and
tailor patient care taking into account patients’ wishes and status of pandemic in the
country.
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Annals of Oncology abstractsBackground: The ongoing SARS-CoV-2 pandemic and ensuing coronavirus disease
(COVID-19) is challenging cancer care and services worldwide.
Methods: A 95 items survey was distributed worldwide by 20 oncologists from 10 of
the most affected countries in order to evaluate the impact on organization of
oncological care.
Results: 109 representatives from oncology centers in 18 countries (62.4% academic
hospitals) filled out the survey (June 17 e July 14, 2020). A swab or gargle test is
systematically performed before day care unit or overnight stay admissions in 27.5%
and 58.7% of the centers, respectively. A local registry (64.2%) and systematic tracing
(77.1%) of infected patients was organized in many centers. Treatment modalities
mostly affected by the pandemic (cancellation/delay) were surgery (44.1%) and
chemotherapy (25.7%). Earlier cessation of palliative treatment was observed in
32.1% of centers, and 64.2 % of participants agree that under-treatment is a major
concern. At the pandemic peak, teleconsultations were performed for follow-up
(94.5%), for oral therapy (92.7%), but also for patients receiving immunotherapy
(57.8%) or chemotherapy (55%). Approximately 82% of participants estimate that
they will continue to use telemedicine. Most participants reported more frequent use
of virtual tumor boards (82%) and oncological team meetings (92%), but 45% disagree
that virtual meetings are an acceptable alternative to live international meetings.
Although 60.9% report reduced clinical activity during the pandemic peak, only 28.4%
had an increased scientific activity. Only 18% of participants estimate that their well-
being will not recover to previous levels by the end of the year; 63% indicate easily
accessible psychological support for caregivers, but only 10% used or planned to use
it. All clinical trial activities are or will soon be reactivated in 72.5% of the centers.
Major study protocol violations/deviations were observed in 27.5% and significant
reductions of clinical trial activities are expected by 37% of centers this year.
Conclusions: COVID-19 has a major impact on organization of patient care, well-being
of caregivers, continued medical education and clinical trial activities in oncology.
Legal entity responsible for the study: The authors.
Funding: Fondation Léon Fredericq.
Disclosure: G. Jerusalem: Advisory/Consultancy, Research grant/Funding (institution), Travel/Ac-
commodation/Expenses: Novartis; Advisory/Consultancy, Research grant/Funding (institution),
Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Research grant/Funding (institu-
tion), Travel/Accommodation/Expenses: Pfizer; Advisory/Consultancy, Travel/Accommodation/Ex-
penses: Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: Amgen; Advisory/
Consultancy, Travel/Accommodation/Expenses: BMS; Advisory/Consultancy, Travel/Accommodation/
Expenses: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo;
Advisory/Consultancy: AbbVie; Travel/Accommodation/Expenses: MedImmune; Travel/Accommo-
dation/Expenses: Merck KGaA. G. Curigliano: Advisory/Consultancy, Speaker Bureau/Expert testi-
mony: Roche; Advisory/Consultancy, Speaker Bureau/Expert testimony: Seattle Genetics; Speaker
Bureau/Expert testimony, Writing engagement: Novartis; Advisory/Consultancy, Speaker Bureau/
Expert testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Pfizer; Advisory/
Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy,
Speaker Bureau/Expert testimony: Samsung; Advisory/Consultancy, Speaker Bureau/Expert testi-
mony: Celltrion; Leadership role, Scientific Affairs Group: Ellipsis; Speaker Bureau/Expert testimony,
Writing engagement: BMS; Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy: Mylan.
M. Campone: Honoraria (self), Advisory/Consultancy: GT1; Honoraria (institution), Advisory/Con-
sultancy: Sanofi; Honoraria (institution), Advisory/Consultancy: Pierre-Favre; Honoraria (institution),
Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Servier; Hono-
raria (institution), Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Honoraria
(institution), Advisory/Consultancy: AbbVie; Honoraria (institution), Advisory/Consultancy: Accord;
Honoraria (institution), Advisory/Consultancy: Pfizer; Speaker Bureau/Expert testimony: Lilly. M.
Martin: Advisory/Consultancy, Research grant/Funding (institution): Roche; Advisory/Consultancy,
Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding
(institution): Puma; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Amgen; Advisory/
Consultancy: Taiho Oncology; Advisory/Consultancy: Daichii Sankyo; Advisory/Consultancy:
PharmaMar; Advisory/Consultancy: Eli Lilly; Advisory/Consultancy: Pfizer. M. Cristofanilli: Advisory/
Consultancy: CytoDyn; Advisory/Consultancy, Speaker Bureau/Expert testimony, Research grant/
Funding (institution): Pfizer; Advisory/Consultancy: Lilly; Advisory/Consultancy: Novartis; Advisory/
Consultancy, Speaker Bureau/Expert testimony: Foundation Medicine; Advisory/Consultancy: G1
Therapeutics; Advisory/Consultancy: Sermionexx; Advisory/Consultancy: Genentch. L. Pusztai:
Honoraria (self), Research grant/Funding (institution), Clinical trial support: Merck; Honoraria (self),
Research grant/Funding (institution), Clinical trial support: AstraZeneca; Honoraria (self), Research
grant/Funding (institution), Clinical trial support: Seattle Genetics; Honoraria (self): Novartis; Hon-
oraria (self), Research grant/Funding (institution), Clinical trial support: Roche Genentech; Honoraria
(self): Eisai; Honoraria (self): Daiichi; Honoraria (self): Syndax; Honoraria (self): Immunomedics. R.
Bartsch: Advisory/Consultancy: Accord; Honoraria (self): AstraZeneca; Advisory/Consultancy,
Research grant/Funding (institution): Daiichi; Advisory/Consultancy, Travel/Accommodation/Ex-
penses: Eli-Lilly; Advisory/Consultancy, Travel/Accommodation/Expenses: MSD; Advisory/Consul-
tancy, Research grant/Funding (institution): Novartis; Advisory/Consultancy, Research grant/Funding
(institution): Roche; Advisory/Consultancy: Puma; Advisory/Consultancy: Pierre-Favre; Advisory/
Consultancy: Sandoz; Advisory/Consultancy: Eisai. M. Tagliamento: Travel/Accommodation/Ex-
penses: Roche; Travel/Accommodation/Expenses: Bristol-Myers Squibb; Travel/Accommodation/
Expenses: AstraZeneca; Travel/Accommodation/Expenses: Takeda; Travel/Accommodation/Ex-
penses: Novartis; Travel/Accommodation/Expenses: Amgen. J. Cortés: Honoraria (self), Advisory/
Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Hono-
raria (self), Advisory/Consultancy: Celgene; Advisory/Consultancy: Cellestia; Advisory/Consultancy,
Research grant/Funding (institution): AstraZeneca; Advisory/Consultancy: Biothera Pharmaceutical;
Advisory/Consultancy: Merus; Advisory/Consultancy: Seattle Genetics; Honoraria (self), Advisory/
Consultancy, Travel/Accommodation/Expenses: Daiichi Sankyo; Advisory/Consultancy: Erytech;
Advisory/Consultancy: Athenex + Polyphor; Advisory/Consultancy, Shareholder/Stockholder/Stock
options: MedSIR; Honoraria (self), Advisory/Consultancy: Lilly; Advisory/Consultancy: Servier; Hon-
oraria (self), Advisory/Consultancy, Research grant/Funding (institution): Merck Sharp Dome; Advi-
sory/Consultancy: GSK; Advisory/Consultancy: Leuko; Advisory/Consultancy: Bioasis; Advisory/
Consultancy: Clovis Oncology; Advisory/Consultancy: Boehringer Ingelheim; Honoraria (self), Travel/
Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: Eisai;
Honoraria (self), Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer;
Honoraria (self): Samsung Bioepis; Research grant/Funding (institution): Ariad Pharmaceuticals;
Research grant/Funding (institution): Baxalta GMBH/Servier Affaires; Research grant/FundingS1206(institution): Bayer Healthcare; Research grant/Funding (institution): F. Hoffmann-La Roche;
Research grant/Funding (institution): Guardanth Health; Research grant/Funding (institution): Piqur
THerapeutics; Research grant/Funding (institution): Puma C; Research grant/Funding (institution):
Queen Mary University of London. E.M. Ciruelos: Advisory/Consultancy, Speaker Bureau/Expert
testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Speaker Bureau/Expert
testimony: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony: Novartis; Advisory/Con-
sultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer. H.S. Rugo:
Research grant/Funding (institution): Eisai; Research grant/Funding (institution): Genentech;
Research grant/Funding (institution): Lilly; Research grant/Funding (institution), Travel/Accommo-
dation/Expenses: MacroGenics; Research grant/Funding (institution): Merck; Research grant/Fund-
ing (institution), Travel/Accommodation/Expenses: Novartis; Research grant/Funding (institution):
Obi Pharma; Research grant/Funding (institution): Odonate Therapeutics; Research grant/Funding
(institution): Immunomedics; Research grant/Funding (institution), Travel/Accommodation/Ex-
penses: Daiichi-Sankyo; Research grant/Funding (institution), Travel/Accommodation/Expenses:
Pfizer; Advisory/Consultancy: Samsung; Advisory/Consultancy: Celtrion; Travel/Accommodation/Ex-
penses: Mylan; Travel/Accommodation/Expenses: AstraZeneca. All other authors have declared no
conflicts of interest.
https://doi.org/10.1016/j.annonc.2020.08.2317LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and
oncology healthcare workers: A multicenter, prospective study
A. Marra1, D.G. Generali2, P. Zagami1, S. Gandini3, V. Cervoni4, S. Venturini5,
S. Morganti1, R. Passerini6, R. Orecchia7, G. Curigliano1
1Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative, Istituto Europeo di
Oncologia IRCCS, Università di Milano, Milan, Italy; 2UO Patologia Mammaria e
Ricerca Traslazionale - Breast Unit, Azienda Socio-Sanitaria Territoriale di Cremona
and University of Trieste, Cremona, Italy; 3Experimental Oncology, Istituto Europeo di
Oncologia IRCCS, Milan, Italy; 4UO Patologia Mammaria e Ricerca Traslazionale -
Breast Unit, Azienda Socio-Sanitaria Territoriale di Cremona and University of Trieste,
Cremona, Italy; 5Dipartimento di Management, Università di Torino, Turin, Italy; 6Di-
vision of Laboratory Medicine, Istituto Europeo di Oncologia IRCCS, Milan, Italy;
7Scientific Direction, Istituto Europeo di Oncologia IRCCS, Milan, Italy
Background: Poor outcomes for patients with cancer and severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19) have been reported
so far. Although anti-SARS-CoV-2 IgG response is usually detectable within three
weeks after infection, limited information on the seroconversion rate of patients with
cancer infected by SARS-CoV-2 is available.
Methods: This is a multicenter, observational, prospective study that included pa-
tients and oncology healthcare workers (HCWs) with SARS-CoV-2 infection confirmed
by RT-PCR or clinical/radiological suspicious of infection as well as patients with
cancer who are considered at high risk for infection. All subjects were tested with the
2019-nCoV IgG/IgM Rapid Test Cassett for the fast detection of IgG and IgM anti-
bodies against SARS-CoV-2. The aim of the study was to evaluate anti-SARS-CoV-2
seroconversion rates by qualitative assay in patients with cancer and HCWs with
confirmed or clinically suspected COVID-19.
Results: At first interim analysis, 166 subjects were enrolled in the study. Cancer
patients and HCWs were 61 (36.7%) and 105 (63.3%), respectively. HCWs were
younger than patients with cancer (median age 41 vs 62 years; P<0.001). Eighty-six
subjects (51.8%) had confirmed SARS-CoV-2 diagnosis by RT-PCR testing on naso-
pharyngeal swab specimen, while forty-nine (29.5%) had a clinical suspicious of
COVID-19 in absence of RT-PCR confirmation. In patients with RT-PCR-confirmed
SARS-CoV-2 infection, 62 (83.8%) were IgG-positive. Neither differences in terms of
IgG positivity (87.9% vs 80.5%; P¼0.39) nor in median time from COVID-19 diagnosis
to IgG detection (23.0 vs 28.0 days; P¼0.21) were found between patients with
cancer and HCWs.
Conclusions: Our data show that SARS-CoV-2-specific IgG antibody response is not
different between cancer patients and healthy subjects. Qualitative rapid test for
antibody detection represents an useful support to RNA RT-PCR testing for the
diagnosis of COVID-19 in high-risk populations, including patients with cancer.
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